Content | Navigation |

Erxi Wu, Ph.D.

Assistant Professor
203 Sudro Hall 
Office Phone: 701.231.7250
Lab Phone: 701.231.8106
Fax: 701.231.8333
Erxi.Wu@ndsu.edu


Research Interests

Dr. Wu's research areas include tumor (i.e., brain tumors, neuroblastoma, and pancreatic cancer) therapeutic targets, drug target proteins, biomarkers, drug discovery, natural products, Traditional Chinese Medicine (TCM)/Complementary and Alternative Medicine (CAM), and pharmacogenomics.


Education

1995-98   Ph.D. in Biochemistry, Sheffield University Medical School, UK 
1998-04   Postdoctoral Research in Cancer Biology, Dana-Farber Cancer Institute, Harvard University, USA
2007-08   Special Graduate Student, Modern Medicine, Massachusetts Institute of Technology, USA  

Academic and Professional Appointments

1983-90   Pharmacologist, Hunan Institute for Drug Control, China
1990-94   Pharmacologist-in-charge, Hunan Institute for Drug Control, China
1992-93   Guest Lecturer, Hunan University, China
1994-95   Visiting Research fellow, CRC Therapeutics Center, The Institute of Cancer Research, University of London, UK
1998-04   Research Associate, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, USA
2006-13   Chair, Advisory Board, Howfond BioPharma, Inc. Boston, USA
2007-       Visiting Professor, Institute of Medicinal Plant Development, Chinese Academy Medical Sciences and Peking Union Medical College, China 
2005-08   Faculty/Staff Scientist, Children’s Hospital Boston and Harvard Medical School, Harvard University, USA
2008-      Tenure-Track Assistant Professor, Department of Pharmaceutical Sciences, North Dakota State University (NDSU), USA

Professional Societies Service Responsibilities and Editorial Activities

1999-      Member, American Association for Cancer Research (AACR)
2002-03  President of the International Association of Biological and Medical Research (IABMR)
2003-04  President, Sino-American Pharmaceutical Professional Association-New England (SAPA-NE) 
2003-04  Vice President, Sino-American Pharmaceutical Professional Association (SAPA)
2005-      Member, Advisory Committee, IABMR
2007-      Board Director of Chinese-American BioMedical Association (CABA)
2006-10  Executive Editorial Member and Reviewer, Journal of Clinical Rehabilitative Tissue Engineering Research
2007-     Ad Hoc Reviewer, Acta Pharmacologica Sinica
2008-     Ad Hoc Reviewer, Translational Research 
2008-     Ad Hoc Reviewer, Journal of Pharmacy and Pharmacology
2008-     Ad Hoc Reviewer, FEBS Letters
2009-     Ad Hoc Reviewer, Cancer Research
2011-     Ad Hoc Reviewer, Current Molecular Medicine
2011-     Ad Hoc Reviewer, International Archives of Medicine
2011-     Ad Hoc Reviewer, Molecular Cancer Research
2011-     Ad Hoc Reviewer, Environmental Toxicology
2011-     Ad Hoc Reviewer, Current Pharmaceutical Design
2011-     Ad Hoc Reviewer, International Journal of Developmental Neuroscience
2011-     Ad Hoc Reviewer, International Journal of Molecular Sciences
2011-14  Faculty mentor for Faculty in Residence Education (F.I.R.E)
2012-     Ad Hoc Reviewer, Molecular Biology Reports
2012-     Ad Hoc Reviewer, Pancreas
2012-     Ad Hoc Reviewer, Bioorganic & Medicinal Chemistry Letters
2012-     Ad Hoc Reviewer, Molecules
2012-     Ad Hoc Reviewer, Journal of Gastroenterology and Hepatology
2012-     Ad Hoc Reviewer, Antioxidants & Redox Signaling
2012-     Guest Editor, Special Issue (Hot Topic), Current Medicinal Chemistry
2012-     Ad Hoc Reviewer, Nutritional Neuroscience
2013-     Board Director of Fargo-Moorhead Table Tennis Association (FMTTA)
2013-     Ad Hoc Reviewer, Academia Journal of Scientific Research
2013-     Ad Hoc Reviewer, F1000Research
2013-     Ad Hoc Reviewer, African Journal of Pharmacy and Pharmacology
2013-     Associate Editor, World Research Journal of Pharmaceutical Research 
2013      Reviewer, “Endocrine Disease” book, published by iConcept Press Ltd 
2013-     Ad Hoc Reviewer, Journal of Nutrigenetics and Nutrigenomics
2013-     Ad Hoc Reviewer, Current Medicinal Chemistry
2013-     Associate Editor, OA Immunology
2013-     Ad Hoc Reviewer, Current Cancer Drug Targets
2013-     Ad Hoc Reviewer, Digestive Diseases and Sciences
2013-     Editorial Board Member, Journal of Hematology and Oncology Research
2013-     Ad Hoc Reviewer, Molecular Cancer Therapeutics
2013-     Ad Hoc Reviewer, International Journal of Cancer
2009-11  Member, Planning, Priorities and Resources Committee, College of Pharmacy, NDSU
2009-     Member, Admissions Committee, College of Pharmacy, NDSU
2012-     Senator, NDSU Faculty Senate
2014-     Ad Hoc Reviewer, Cancer Medicine
2014-     Ad Hoc Reviewer, Drug Resistance Updates
2014-     Ad Hoc Reviewer, BMC Cancer
2014-     Ad Hoc Reviewer, Research in Veterinary Science
2014-     Ad Hoc Reviewer, NANO
2014-     Ad Hoc Reviewer, Oncotarget
2014-     Ad Hoc Reviewer, Drug Discovery Today
2014      Faculty Delegate for NDSU, AACP 2014 Annual Meeting

Awards and Honors

1983       Outstanding student award, Hunan Normal University
1993       Sino-British Friendship Scholarship Scheme (SBFSS) Scholarship, Chinese and British Governments (to undertake research in Britain for one year)
1995-98  ORS (Overseas Research Scholarship) Scholarship, British Government
1998       Travel Award, NATO Advanced Study Institute
2002       Travel Award, Gordon Research Conference: Proteolytic Enzymes & Their Inhibitors
2003       SAPA 2003 Excellence Service Award
2004       SAPA 2004 Excellence Service Award
2005       IABMR Outstanding Leadership Award
2007       Outstanding Poster Presentation Award, 4th IABMR Annual Conference
2005-07   NIH National Library of Medicine Fellowship 
2006-08   AOL Research Grant for studying biomarkers in cancer and other diseases (PI)
2008-      NDSU New Faculty Start-up Award (PI)
2009-11   NSF ND EPSCoR New Faculty Grant (PI)
2009-10   NDSU Professional Development Grant (PI)
2010-11   NSF ND EPSCoR Infrastructure Improvement Program-Seed Grant (PI)
2010-11   Sigma-Tau Medical Educational Grant (PI)
2010-      NSF MRI Grant (Minor User; PI: S. Mallik)
2011-      COBRE- sponsored Center for Visual and Cognitive Neuroscience Project Grant (PI)
2011-12   NDSU Provost Travel and Research Fund 
2012-13   NDSU Provost Travel and Research Fund 
2012-      COBRE-sponsored Center of Protease Research Project Grant (PI)
2013-14   NDSU Provost Travel and Research Fund 

Featured News on Our Research 

http://www.ndsu.edu/news/banner_stories/ErxiWuresearch/ 

Invited Lectures/Seminars

1997   
Expression of members of the novel membrane linked metalloproteinase family A Disintegrin and Metalloproteinase in cells derived from a range of haematological malignancies.  Shanghai Research Centre of Biotechnology, Chinese Academy of Sciences, Shanghai, China. July 4, 1997

Proteins with a Disintegrin and Metalloproteinase domain and drugs. Hunan Institute and Drug Control and Hunan Society of Pharmacology, Changsha, China. July 11, 1997

Proteins with a Disintegrin and Metalloproteinase domain and drugs. Hunan Medicine and Drug Industry Institute, Changsha, China, July 11, 1997

Expression of members of the novel membrane linked metalloproteinase family A Disintegrin and Metalloproteinase in cells derived from a range of haematological malignancies. “The 5th Symposium on Life Sciences and Biotechnology for Chinese Bio-scientists Overseas & Returned”. June 27-30, 1997, Peking University, Beijing, China

ADAM: A novel membrane linked metalloproteinase family. The sixth Annual Conference of Life Science Society for Chinese Bioscientists in the UK (LSSCB), Oxford, UK, September 20-21, 1997

1998   
ADAM10, ADAM12 and ADAM15 gene expression in the U937 human histiocytic lymphoma cell line: regulation of gene expression by IL10, IL4 and PMA. Conference on “Intermolecular Cross-Talk in Tumor Metastasis”.  Athens, Greece, July 24-August 3, 1998

2002   
PKCbeta: a rational therapeutic target in Diffuse Large B-cell Lymphoma. Selected for oral presentation by American Society of Hematology annual meeting on Dec, 10, 2002, Pennsylvania, USA

2003  
Novel Approaches to Treating Cancer: Rational Treatment Targets and Proteasome Inhibition. Wuhan Bio-Products Institute, Wuhan, Sept, 16, 2003

Novel Approaches to Treating Cancer: Rational Treatment Targets and Proteasome Inhibition. Hunan Institute for Drug Control, Changsha, Sept 19, 2003

Novel Approaches to Treating Cancer: Rational Treatment Targets and Proteasome Inhibition. Hunan Medical University, Changsha, Sept 24, 2003

Novel Approaches to Treating Cancer: Rational Treatment Targets and Proteasome Inhibition. Hunan Agricultural University, Colleges of Sciences and Graduate Studies, Changsha, Sept 25, 2003

Novel Approaches to Treating Cancer: Rational Treatment Targets and Proteasome Inhibition. Hunan Tumor Hospital, Changsha, Sept 25, 2003

2004   
Targets Identification & Validation: A Case Study of Diffuse Large B-cell Lymphoma. The 2nd International Forum on Advanced Pharmaceutical Technology and Business Development Strategies, Haikou, July 22-24, 2004

Targets Identification & Validation: A Case Study of Diffuse Large B-cell Lymphoma. “Shanghai 2004 Bio-Forum/Tri-Conferences”.  Shanghai, July 23-27, 2004

2005   
Modern Technology in Drug Discovery. “The 2nd International Conference on the Modernization of Traditional Chinese Medicine” Chengdu, China. Sept 25-27, 2005

Modern Technology in Drug Discovery. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences. Beijing, China. Sept 22, 2005

2006  
Mechanisms of Anticancer Traditional Chinese Medicine, Featured presentation in the third International Association of Biological and Medical Research (IABMR). Boston, MA. Dec 7, 2006

2007   
Mechanisms of Anticancer Natural Products. Drug Discovery & Development: From Small Molecules to Biotherapeutics, SAPA-NE, Boston. Feb 24, 2007

Mechanisms of Anticancer TCM. Invited speaker, SAPA 2007 China Conference, Shanghai. July 3, 2007

2008   
Cancer Therapeutics: Target and Treatment. Invited speaker, Weekly Seminar in Pharmaceutics Sciences, Northeastern University, Boston. Jan 31, 2008

Platelet-derived growth factor signaling & targeted cancer therapy. 13th Annual Conference of Chinese Biopharmaceutical Association,10th Shanghai Bio-Forum, Shanghai. May 28-30, 2008

Cancer therapeutic targets, biomarkers and drug discovery, IABMR Member Symposium, Boston. June 7, 2008

2009   
Cancer Therapeutics: Target and Drug Discovery, NDSU Molecular and Cellular Biology Program, Fargo. Oct 22, 2009

2012   
Cancer Therapeutics: Target and Drug Discovery, Sanford Research and Sanford Medical School of South Dakota, Sioux Falls.  Jan 19-20, 2012

Cancer Therapeutics: Current Status, the First Annual Meeting of Society for Combined Therapy East Meets West, Boston. Feb 4, 2012 

Platelet-derived growth factor (PDGF) signaling in medulloblastoma, Professor David W. Li laboratory, College of Medicine, University of Nebraska, Omaha, June 8, 2012

Platelet-derived growth factor (PDGF) signaling in medulloblastoma, College of Engineering and Architecture, North Dakota State University, Fargo, ND September 12, 2012

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma, The Scott & White/Texas A&M Health Science Center/College of Medicine Center for Cell Death and Differentiation, Temple, TX. November 27-29, 2012

2013   
Therapeutic target and drug discovery in medulloblastoma and neuroblastoma, College of Biological Sciences and Engineering. South China University of Technology, Guangzhou, China. January 28, 2013

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma, COBRE Center of Proteinase Research, NDSU, Fargo, February  5, 2013.

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma, Hunan Institute for Food and Drug Control, Changsha, August 2, 2013.

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma, Xi’an Jiaotong University Medical School, Xi’an, August 5, 2013. 

2014   
How to enter American graduate program and do research in the USA. Xi’an Jiaotong University Medical School, Xi’an. Jul 8, 2014

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma. Annual meeting by Henan Neurological Physicians Association. Zhengzhou. Aug 28-Sep1, 2014 (delivered on Aug 30, 2014) 

Therapeutic target and drug discovery in medulloblastoma and neuroblastoma. 2nd Wuxi Global BioForum.by Chinese-American BioMedical Association (CABA) with All-China Federation of Returned Overseas Chinese, Jiangsu Federation of Returned Overseas Chinese, and Wuxi Metropolitan Government. Wuxi. Oct 9-11, 2014

2015 
Novel rational therapeutic targets in medulloblastoma and neuroblastoma, Pharmacy School, Concordia University Wisconsin, Mequon. Jan 21, 2015

Publications 

1.  Wu E, Zhang N, Ge W, Liang X, Cai Y. Studies on the trace elements in Lonicera japonica and L. macranthoides. Chinese Traditional and Herbal Drugs. 19(6). 1988 (“Outstanding Paper” awarded by Hunan Trace Elements and Health Study Society in 1989).

2.  Zhang N, Wu E, Ge W, Liang X, Cai Y. Studies on the trace elements in Paeonia lactiflora and their relations with quality of the crude drug. Traditional Chinese Medicine and Clinical Research. No.1. 1988.

3.  Zhang N, Wu E, Ge W, Liang X, Cai Y. The study on the relationship between content of trace elements and quality in 4 species of Traditional Chinese Medicine used for hepatitis. Traditional Chinese Medicine and Clinical Research. No.2. 1988.

4.  Zhang N, Wu E. A Review on studies of trace elements of Chinese Materia Medica. Traditional Chinese Medicine and Clinical Research, No.4. 1988.

5.  Wu E, Zhang N. Pharmacognostical studies on the natural Bezoar and its similar gallstone. Traditional Chinese Medicine and Clinical Research. No.1. 1992.

6.  Zhang N. et al. Hunan Traditional Chinese Medicine Criteria (one of contributors). Hunan Science and Technology Press. Hunan, China. 1993.

7.  Wu E, Croucher PI, McKie N. Expression of members of the novel membrane linked metalloproteinase family A disintegrin and metalloproteinase in cells derived from a range of haematological malignancies. Biochemical and Biophysical Research Communications. 235 (2): 437-442. 1997.

8.  Millichip M, Dallas DJ, Wu E, Dale S, McKie N. The metallo-disintegrin ADAM10 (MADM) from bovine kidney possesses in vitro type IV collagenase activity. Biochemical and Biophysical Research Communications. 245:594-598. 1998.

9.  Wang F, Wu E. Quantitative determination of Ginsenoside Rg1 in Baoyuanchangyang capsule by thin layer chromatography scanning. Life Science Research. 3(3):177-181. 1998.

10.  Wu E, McKie N. ADAMs: a novel protein family with metalloproteinase and adhesion domains. 263-290. In Intermolecular Cross-Talk in Tumor Metastasis. NATO Science Series. Editors: G. Skouteris - G. Nicolson, IOS press (Amsterdam, Netherlands). 1999.

11.  Wu E, McKie N. ADAM10 (MADM), ADAM12 (mdc9) and ADAM15 (metargidin) expression in the U937 human histiocytic lymphoma cell line: regulation of gene expression by IL10, IL4, and PMA. 291-306. In Intermolecular Cross-Talk in Tumor Metastasis. NATO Science Series. Editors: G. Skouteris - G. Nicolson, IOS press (Amsterdam, Netherlands).1999.

12.  Wu E*, Wang F, McKie N. Matrix metalloproteinases (Monograph). Life Science Research. 3(3):175-194, 1999 (corresponding author).

13.  Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. Journal of Cellular Biochemistry, 82(4):549-555. 2001.

14.  Chen N, Ma WY, She QB, Wu E, Liu G, Bode AM, Dong Z. Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoyl-phorbol-13-acetate-induced signal transduction. Journal of Biological Chemistry. 276(50): 46722-46728. 2001.

15.  Fromigue O, Louis K, Wu E, Nathalie B, Agnes L, Shipp MA, Auberger P, Mari B. Active Stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of P42/p44 MAP-kinase. International Journal of Cancer. 106(3): 355-363. 2003.

16.  Wu E*, Yin D, Wang F. Applications of RNA interference in biomedical research. Life Science Research, 9(2): 95-98. 2005 (*corresponding author).

17.  Wu E*, Yin D, Wang F. Recent development in RNAi. Trends in Bio/Pharmaceutical Industry, 3:25-27, 2005 (*corresponding author).

18.  Tian Z, Zhou L, Huang F, Chen S, Yang J, Wu E, Xiao P, Yang M. Anti-cancer activity and mechanisms of 25-anhydrocimigenol-3-O-beta-D-xylopyranoside isolated from Souliea vaginata on hepatomas. Anti-Cancer Drugs. 17(5): 545-551. 2006.

19.  Tian Z, Si J, Chen S, Yang M, Xiao P, Wu E. Cytotoxicity and mechanism of 23-O-acetylcimigenol-3-O-β-D-xylopyranoside on HepG2 cells. China Journal of Chinese Materia Medica, 31(21):1818-1821. 2006.

20.  Tian Z*, Liu Y, Chen S, Yang J, Xiao P, Wang L, Wu E*. Cytotoxicity of two triterpenoids from Nigella glandulifera. Molecules. 11(9): 693-699. 2006 (*corresponding author).

21.  Zhang H, Bajrazzewski N*, Wu E*, Wang H, Moseman, AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRs are critical for PI3K/AKT activation and negatively regulated by mTOR. Journal of Clinical Investigation. 117(3):730-738, 2007 (*equal author).

22.  Tian Z, Xu L, Chen S, Zhou L, Yang M, Chen S, Xiao P, Wu E. Cytotoxic activity of schisandrolic and isoschisandrolic acids involves induction of apoptosis. Chemotherapy, 53(4): 257-262. 2007.

23.  Tian Z*, Pan R, Chang Q, Si J, Xiao P, Wu E*. Cimicifuga foetida extract inhibits proliferation of hepatocellular carcinoma via induction of cell cycle arrest and apoptosis. Journal of Ethnopharmacology. 114(2):227-233. 2007 (*corresponding author).

24.  Tian Z, Si J, Chang Q, Zhou L, Chen S, Xiao P, Wu E*. Antitumor activity and mechanisms of action of total glycosides from aerial part of Cimicifuga dahurica targeted against hepatoma. BMC Cancer, 7:237. 2007 (*corresponding author).

25.  Tian Z, Shen J, Moseman AP, Yang QL, Yang JS, Xiao PG, Wu E*, Kohane IS. Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells. International Journal of Cancer. 122(1):31-8, 2008 (*corresponding author).

26.  Wu E, Palmer N, Moseman AP, Tian Z, Galdzicki M, Wang X, Berger B, Zhang H, Kohane IS. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One, 3(11):e3794. 2008.

27.  Wu E*. Remembering Dr. Judah Folkman, Father of angiogenesis. Trends in Bio/Pharmaceutical Industry. 2008 (*corresponding author).

28.  Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 57(11):3013-3024. 2008.

29.  Tian Z, An N, Zhou B, Xiao P, Kohane IS, Wu E*. Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemotherapy and Pharmacology. 63 (6):1131-1139. 2009 (*corresponding author).

30.  Tian Z, Palmer N, Schmid P, Yao H, Galdzichi M, Berger B*, Wu E*, Kohane IS. A practical platform for blood biomarker study by using global gene expression profiling of peripheral whole blood. PLoS One. 4(4):e5157. 2009 (*corresponding author).

31.  Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Molecular Cancer. 8:81. 2009.

32.  Yu P, Liu Q, Liu K, Yagasaki K, Wu E, Zhang G. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 59(3):219-29. 2009.

33.  Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Sun Q, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. Journal of Clinical Investigation. 120 (1):103-14. 2010.

34.  Fiorina P, Jurewicz M, Vergani A, Petrelli A, Carvello M, D'Addio F, Godwin JG, Law K, Wu E, Tian Z, Thoma G, Kovarik J, La Rosa S, Capella C, Rodig S, Zerwes HG, Sayegh MH, Abdi R. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. Journal of Immunology. 186 (1):121-123. 2011.

35.  Zhang M, Ma Q, Hu HT, Zhang D, Li JH, Ma GD, Bhat K, Wu E. Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1α under normoxic condition. Cancer Letters. 303(2):108-117. 2011.

36.  Ferrazzi F, Engel FB, Wu E, Moseman AP, Kohane IS, Bellazzi R, Ramoni MF. Inferring cell cycle feedback regulation from gene expression data. Journal of Biomedical Informatics. 44(4):565-75. 2011.

37.  Li J, Ma Q*, Liu H, Guo K, Li K, Li W, Han L, Wang F, Wu E*. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One. 6(2):e17385. 2011 (*corresponding author).

38.  Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. Journal of Neuro-Oncology. 105(2):261-273. 2011.

39.  Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, Wu E. β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. European Journal of Pharmacology. 665(1-3):1-7. 2011.

40.  Tian Z*, Shen J, Wang F, Xiao P, Yang J, Lei H, Kazlauskas A, Kohane IS, Wu E*. Cambogin is preferentially cytotoxic to cells expressing PDGFR.  PLoS One. 6(6): e21370. 2011 (*corresponding author).

41.  Purwaha P, Gu Y, Kelavkar U, Kang JX, Law B, Wu E, Qian SY. LC/ESR/MS study of pH-dependent radical generation from 15-LOX-catalyzed DPA peroxidation. Free Radical Biology & Medicine. 51:1461–1470. 2011.

42.  Wang F, Bhat K, Doucette M, Zhou S, Gu Y, Law B, Liu X, Wong ET, Kang JX, Hsieh TC, Qian SY, Wu E*. Docosahexaenoic Acid (DHA) sensitizes brain tumor cells to etoposide-induced apoptosis. Current Molecular Medicine. 11(6):503-511. 2011 (*corresponding author).

43.  Shan T, Ma Q, Guo K, Liu J, Li W, Wang F, Wu E. Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs. Current Molecular Medicine. 11(8):666-677. 2011.

44.  Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S, Wu E. High glucose promotes pancreatic cancer cells proliferation via induction the expression of EGF and the transactivation of EGFR. PLoS One. 6(11):e27074. 2011.

45.  Zhang D, Ma Q*, Wang Z, Zhang M, Guo K, Wang F, Wu E*. β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway. Molecular Cancer. 10(1):146. 2011 (*corresponding author).

46.  Tian Z, Sun Y, Xiao P, Wu E. Recent advances in natural bioactive cycloartane triterpenoids. Recent Progress in Medicinal Plants Volume 31: Mechanism and Action of Phytoconstituents (Editors: Awaad, A. S.; Kaushik, G.; Govil, J. N). Studium Press. 49-63. 2011.

47.  Li W, Ma Q, Liu J, Han L, Ma G, Liu H, Shan T, Xie K, Wu E. Hyperglycemia as a mechanism of pancreatic cancer metastasis. Frontiers in Bioscience. 17:1761-1774. 2012.

48.  Li W, Ma Q, Wu E. Perspectives on the role of photodynamic therapy in the treatment of pancreatic cancer. International Journal of Photoenergy. Article ID 637429, 9 pages, 2012.

49.  Zhang G*, Wang S, Wan X, Zhang Y, Li J, Liu K, Wang F, Liu K, Yang C, Liu Q, Yu P, Huang Y, Wang S, Jiang P, Qu Z, Luan J, Duan H, Hou A, Zhang L, Jin S, Hsieh T, Wu E*. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Current Molecular Medicine. 12(2):163-76. 2012 (*corresponding author).

50.  Bhat K, Wang F*, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E*. Advances in biomarker research for pancreatic cancer. Current Pharmaceutical Design. 18(17):2439-2451. 2012 (*corresponding author).

51.  Liu H, Ma Q, Xu Q, Lei J, Li X, Wang Z, Wu E. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Current Pharmaceutical Design. 18(17):2395-2403. 2012.

52.  Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Current Pharmaceutical Design. 18(17):2404-2415. 2102.

53.  Zhang R, Wang Z, Howson PA, Xia Z, Zhou S, Wu E, Xia Z, Hu Y. Smilagenin attenuates beta amyloid (25-35)-induced degeneration of neuronal cells via stimulating the gene expression of brain-derived neurotrophic factor. Neuroscience. 210:275-85. 2012.

54.  Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, Wang Z. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Letters. 322(2):169-176. 2012.

55.  Liu J, Zhang M, Ma Q, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis. European Journal of Cancer. 48(15):2328-2338. 2012.

56.  Doonan B, Wu E, Wu J. Prevention and management of obesity by isoflavones. In Food and Nutritional Components in Focus: Chemistry, Analysis, Function and Effects (The Royal Society of Chemistry). Chapter 33, 535-538. 2012.

57.  Li X, Ma Q, Duan W, Liu H, Xu H, Wu E. Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment. Critical Reviews™ in Eukaryotic Gene Expression. 22(2):97-108. 2102.

58.  Lun M, Lok E, Gautam S, Wu E, Wong ET. Reply to Dr. Beauchesne. Journal of Neuro-Oncology. 109:595. 2012.

59.  Li X, Ma G, Ma Q*, Li W, Liu J, Han J, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E*. Neurotransmitter substance P in nerves mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Molecular Cancer Research. 11(3):294-302. 2013 (*corresponding author).

60.  Wu E*, Zhou S, Bhat K, Ma Q. CA 19-9 and pancreatic cancer. Clinical Advances in Hematology & Oncology. Invited. 11(1): 53–55. 2013 (*corresponding author).

61.  Huang H, Weaver A, Wu E, Gao H, Fan W, Wu M. Lipid based signaling modulates DNA repair response and survival in host cells and in mice. American Journal of Respiratory Cell and Molecular Biology. 49(5):798-807. 2013.

62.  Wang X, Wu E, Wu J, Wang T, Hsieh H, Liu X. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PLoS One. 8(6): e65686. 2013.

63.  Lei J, Ma J, Ma Q, Li X, Liu H, Xu Q, Duan W, Sun Q, Xu J, Wu Z, Wu E. Hedgehog signaling regulates hypoxia induced EMT and invasion in pancreatic cancer cells via a ligand-independent manner. Molecular Cancer. 12(1):66. 2013

64.  Shan T, Ma J, Ma Q*, Guo K, Guo J, Li X, Li W, Liu J, Huang C, Wang F, Wu E*. β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Current Molecular Medicine. 13(6). 1023-1034. 2013 (*corresponding author).

65.  Wu E*. Discovering new anticancer activities from old drugs. Current Medicinal Chemistry. 20(33):4093-4094. 2013 (*corresponding author).

66.  Zhou S, Wang F*, Hsieh T, Wu JM, Wu E*. Thalidomide–a notorious sedative to a wonder anticancer drug. Current Medicinal Chemistry. 20(33):4102-8, 2013 (*corresponding author).

67.  Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, Wu E*. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Current Medicinal Chemistry. 20(33):4095-4101. 2013 (*corresponding author).

68.  Guo J, Ma Z, Ma Q*, Wu Z, Fan P, Zhou X, Chen L, Zhou S, Goltzman D, Miao D, Wu E*. 1,25(OH)2D3 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Current Medicinal Chemistry. 20(33):4131-4141. 2013 (*corresponding author).

69.  Han L, Peng B, Ma Q, Ma J, Li J, Li W, Duan W, Chen C, Liu J, Xu Q, Laporte K, Li Z, Wu E. Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of E-cadherin in pancreatic cancer cells. Current Medicinal Chemistry. 20(33):4142-4152. 2013. 

70.  Li W, Ma J, Ma Q, Han L, Liu J, Xu Q, Duan W, Yu S, Li B, Wang F, Wu E. Resveratrol inhibits epithelial-mesenchymal transition of pancreatic cancer cells via suppressing PI-3K/Akt/NF-κB pathway. Current Medicinal Chemistry. 20(33):4185-4194. 2013.

71.  Hsieh TC, Bennett DJ, Lee YS, Wu E, Wu JM. In silico and biochemical analyses identify quinone reductase 2 as a target of piceatannol. Current Medicinal Chemistry. 20(33):4195-4202. 2013.

72.  Li X, Zhou X, Ye Y, Li Y, Li J, Privratsky B, Wu E, Gao H, Huang C, Wu M. Lyn cooperating with lipid rafts regulates inflammatory response in Klebsiella pneumoniae infection through the p38/NF-kB pathway. European Journal of Immunology. 44(3):763-773. 2013.

73.  Aquilato A, Lopez V, Doonan B, Hsieh TC, Pinto JT, Wu E, Wu JM. Dietary polyphenols as adjunctive strategy targeting BRAF mutation in treatment of melanoma, in Polyphenols in Human Health and Disease (Editors: Ronald Ross Watson, Victor R. Preedy, and Sherma Zibadi) (Elsevier). Chapter 102. 1353-1365. 2014.

74.  Lei J, Huo X, Duan W, Xu Q, Li R, Ma J, Li X, Han L, Li W, Sun Q, Wu E, Ma Q. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Cancer Letters. 347(1):129-138. 2014.

75. Vergani A, Gatti F, Lee KM, D'Addio F, Tezza S, Chin M, Bassi R, Tian Z, Wu E, Maffi P, Ben Nasr M, Kim JI, Secchi A, Markmann JF, Rothstein DM, Turka LA, Sayegh MH, Fiorina P. TIM4 regulates the anti-islet Th2 alloimmune response. Cell Transplantation. Mar 7, 2014.

76.  Xu Y, Qi J, Yang X, Wu E, Qian S. Free radical derivatives formed from cyclooxygenase-catalyzed dihomo-γ-linolenic acid peroxidation can attenuate colon cancer cell growth and enhance 5-fluorouracil'scytotoxicity. Redox Biology. 2: 610–618. 2014.

77.  Duan W, Ma J, Ma Q*, Xu Q, Lei J, Han L, Li X, Wang Z, Wu Z, Lv S, Ma Z, Liu M, Wang F, Wu E*. The activation of β1-integrin by type I collagen coupling with the hedgehog pathway promotes the epithelial-mesenchymal transition in pancreatic cancer. Current Cancer Drug Targets. 14(4):446-457. 2014 (*corresponding author). 

78.  Xu Q, Ma J, Lei J, Duan W, Sheng L, Chen X, Hu A, Wang Z, Wu Z, Wu E, Ma Q, Li X. Alpha-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by down-regulating the PI3K/Akt pathway. BioMed Research International. 2014:546353. 2014.

79.  Gong L, Ji WK, Hu XH, Hu WF, Tang XC, Huang ZX, Li L, Liu M, Xiang SH, Wu E, Woodward Z, Liu YZ, Nguyen QD, Li DW. Sumoylation differentially regulates Sp1 to control cell differentiation. Proceedings of the National Academy of Sciences of the United States of America. 111(15):5574-5579. 2014.

80.  Duan W, Lei J, Xu Q, Yu Y, Li R, Wu E, Ma Q. Hyperglycemia, a Neglected Factor During Cancer Progression. BioMed Research International. 461917. 2014.

81.  Zhou S, Wang F, Zhang Y, Johnson M, Qian S, Wu M, Wu E*. Salinomycin suppresses PDGFRβ, c-Myc, and Notch signaling in human medulloblastoma. Austin Journal of Pharmacology and Therapeutics. 2 (3).7. 2014 . (*corresponding author).

82.  Li W, Wu Z, Ma Q*, Liu J, Xu Q, Han L, Duan W, Lv Y, Wang F, Reindl KM, Wu E*. Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer. Current Cancer Drug Targets. 14(4):348-56. 2014 (*corresponding author). 

83.  Wang W, Ye Y, Li J, Li X, Zhou X, Tan D, Jin Y, Wu E, Cui Q, Wu M. Lyn regulates cytotoxicity and inflammation in respiratory epithelial cells challenged by cigarette smoke extracts. Current Molecular Medicine. 14(5):663-672. 2014.

84.  Li X, Wang Z, Ma Q, Xu Q, Liu H, Duan W, Lei J, Ma J, Wang X, Lv S, Han L, Li W, Guo J, Guo K, Zhang D, Wu E, Xie K. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clinical Cancer Research. Aug 15; 20(16):4326-38. 2014.

85.  Zhao T, Li Y, Liu B, Wu E, Sillesen M, Velmahos GC, Alam HB. Histone Deacetylase Inhibitor Treatment Attenuates Coagulation Imbalance in a Lethal Sepsis Model. Surgery. Aug; 156(2):214-20. 2014.

86.  Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Ma Q, Wu E. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cell to gemcitabine via inhibition of NF-κB signaling. BMC Cancer. Sep 20; 14:686. 2014.

87.  Zhang G, Ye X, Ji D, Zhang H, Sun F, Shang C, Zhang Y, Wu E, Wang F, Wu F, Tian H, Liu X, Chen L, Liu K, Wang Y, Liu H, Zhang W, Guan Y, Wang Q, Zhao X, Wan X. Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives. Oncotarget. Sep 30; 5(18):8528-43. 2014

88.  Hsieh TC, Lin CY, Dennett DJ, Wu E, Wu JM. Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One. 9(6):e101070. 2014.

89.  Zhou P, Wu E, Velmahos GC, Alam HB, Li Y. Histone Cleavage as a Mechanism for Epigenetic Regulation: Current Insights and Perspectives. Current Molecular Medicine.  Oct 15, 2014.

90.  Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z, Nan L, Li X, Wang Z, Huo X, Han L, Wu Z, Wu E, Ma Q. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget. Dec 1, 2014

91.  Zhou S, Wang F, Wu E*. Combination of Etoposide and Docosahexaenoic Acid via Targeting PI3K/MAPK Pathway May Be A New Therapeutic Strategy for Medulloblastoma. iConcept Medical Diagnosis and Treatment. 2:(2). Dec 2014 (*corresponding author).

92.  Wang F, Remke, Bhat K, Wong ET, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke ST, Li DW, Wu L, Hawkins C, Kohane IS, Wu M, Wu JM, Taylor MD*, Wu E*. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. (*corresponding author). Oncotarget. Dec 17, 2014.

93.  Xu Q, Wang Z, Chen X, Duan W, Lei J, Zhong L,  Li X, Sheng L, Ma J, Han L,  Li W, Zhang L, Guo K, Ma Z, Wu Z, Wu E, Ma Q. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway modulates perineural invasion in pancreatic cancer. Oncotarget. Dec 26, 2014.

94.  Li J, Huo X, Ma J, Han L, Xu Q, Lei J, Duan W, Li W, Wang F, Wu E, Ma Q. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Cancer Biology & Therapy. Minor revision.

95.  Zhang D, Lei J, Ma J, Xu Q, Duan W, Li X, Chen X, Sheng L, Wu E, Wang Z, Ma Q. β2-Adrenogenic signaling regulates NNK-induced pancreatic cancer progression via stabilization of HIF-1. HIF-1α. Scientific Reports. Minor revision.

96.  Li X, Wu Z, Sha H, Wang Z, Ma Z, Wu E, Ma Q. Protective effects of polyenoylphosphatidylcholine in rats with severe acute pancreatitis. Pancreas . Revision.

97.  Ding X, Ma M, Teng J, Yin J, Zhou S, Zhang Y, Wu E*, Wang X*. Exposure to ALS-FTD-CSF induced the formation of TDP-43 aggregates in U251 cells via exosome and TNT-like structure. Experimental Neurology. Revision. (*corresponding author).

98.  Li W, Ma Z, Ma J, Xu Q, Duan W, Li X, Lv Y, Wu E, Huo X, Ma Q. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Submitted.

99.  Zhang L, Ma Q, Ma J, Han L, Yu S, Xu Q, Lei J, Duan W, Wang F, Wu E, Li X. Clinicopathologic significance and protective effect on ROS -causing damage of Nrf2 and autophagy in Pancreatic ductal adenocarcinoma. Submitted. 

100.  Yu Y, Ma G, Ma J, Li R, Shen L, Chen X, Wu E, Wu Z. Gremlin 1 as an Emerging Target for Pancreatic Cancer. Submitted.

101.  Liu J, Wang X, Ma Q, Li w, Wang X Feng X, Den M, Wang F, Wu E. Prognostic significance of ERβ expression in patients with breast cancer: a systematic review and meta-analysis. Submitted.

102.  Qin Y, Ma Q, Wu E. Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer Mia PaCa-2 cells in vitro by blocking Hedgehog signaling pathway. Submitted. 

103.  Zhang L, Ma Z, Ma J, Xu Q, Lei J, Duan W, Han L, Yu S, Wang F, Wu E, Ma Q, Li X. Protective effect of Nrf2 and autophagy on ROS-mediated damage in pancreatic ductal adenocarcinoma. Submitted.

104.  Han L, Ma J, Duan W, Zhang L, Yu S, Xu Q, Lei J, Li X, Huo X, Wang Z, Wu Z, Wu E, Ma Q. Involvement of pancreatic stellate cells in pancreatic cancer pain via activation of sHH signaling pathway and regulation of TRPV1, SP, and CGRP. Submitted.

105.  Wang X, Ma M, Teng J, Shao F, Zhou S, Zhang Y, Wu E*, Ding *X. Numb induces E-cadherin adhesion dissolution、cytoskeleton reorganization and migration enhancement in tubular epithelial cells: implication in renal fibrosis. Submitted.  (*corresponding author).

 

Teaching

PSCI412/612 Chemotherapeutic/Infectious Disease Pharmacodynamics
PSCI 417/617 Pharmacogenomics

Intellectual property to NDSU

I. RET-418. Identification of salinomycin's novel therapeutic binding targets in cancers.2012
II. RFT-409. Discovery of novel prognostic factors in medulloblastoma. 2012
III. RFT-406. Discovery of Tea Epigallocatechin-3-Gallate EGCG as an anticancer agent for clinic use. 2012
IV. RFT-386. Discovery of a novel method for identification of drug binding targets and DNA binding proteins. 2011
V. RFT-384. Identification of cambogin as a novel anti-cancer agent. 2011


Student Focused. Land Grant. Research University.

Follow NDSU
  • Facebook
  • Twitter
  • RSS
  • Google Maps

North Dakota State University
Phone: +1 (701) 231-7661 / Fax: (701) 231-8333
Campus address: Sudro Hall 116
Physical/delivery address: 1401 Albrecht Blvd, Fargo, ND 58102
Mailing address: NDSU Dept. 2665 / PO Box 6050 / Fargo, ND 58108-6050
Page manager: Pharmaceutical Sciences
Published by North Dakota State University

Last Updated: Friday, January 23, 2015 11:26:10 AM